Inspire Investing LLC Decreases Stake in Royalty Pharma PLC $RPRX

Inspire Investing LLC lessened its holdings in shares of Royalty Pharma PLC (NASDAQ:RPRX) by 82.8% in the first quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 7,093 shares of the biopharmaceutical company’s stock after selling 34,077 shares during the quarter. Inspire Investing LLC’s holdings in Royalty Pharma were worth $340,000 as of its most recent filing with the SEC.

Several other hedge funds have also recently bought and sold shares of the business. Barton Investment Management acquired a new stake in Royalty Pharma in the first quarter worth about $905,000. Nomura Asset Management Co. Ltd. lifted its position in Royalty Pharma by 16.2% in the fourth quarter. Nomura Asset Management Co. Ltd. now owns 172,418 shares of the biopharmaceutical company’s stock worth $6,662,000 after purchasing an additional 24,048 shares during the period. Fideuram Intesa Sanpaolo Private Banking S.P.A. bought a new position in Royalty Pharma during the 4th quarter valued at $4,923,000. Qsemble Capital Management LP acquired a new position in shares of Royalty Pharma during the 4th quarter valued at $2,875,000. Finally, Regal Partners Ltd increased its position in shares of Royalty Pharma by 6.7% during the 3rd quarter. Regal Partners Ltd now owns 1,435,126 shares of the biopharmaceutical company’s stock valued at $50,631,000 after purchasing an additional 89,930 shares during the period. Hedge funds and other institutional investors own 54.35% of the company’s stock.

Analyst Upgrades and Downgrades

Several brokerages have recently weighed in on RPRX. UBS Group upped their price objective on Royalty Pharma from $51.00 to $57.00 and gave the company a “buy” rating in a report on Tuesday, April 21st. Weiss Ratings downgraded shares of Royalty Pharma from a “buy (b)” rating to a “buy (b-)” rating in a report on Friday, May 15th. Morgan Stanley lifted their price objective on shares of Royalty Pharma from $61.00 to $63.00 and gave the stock an “overweight” rating in a research note on Friday, April 10th. Wall Street Zen upgraded shares of Royalty Pharma from a “buy” rating to a “strong-buy” rating in a report on Saturday, May 9th. Finally, JPMorgan Chase & Co. lifted their price target on Royalty Pharma from $50.00 to $58.00 and gave the stock an “overweight” rating in a research note on Thursday, May 7th. Seven equities research analysts have rated the stock with a Buy rating, Based on data from MarketBeat, Royalty Pharma has an average rating of “Buy” and a consensus target price of $53.71.

Royalty Pharma Price Performance

Shares of RPRX stock opened at $57.77 on Monday. The stock’s 50 day simple moving average is $53.56 and its 200 day simple moving average is $47.30. Royalty Pharma PLC has a twelve month low of $34.08 and a twelve month high of $57.80. The company has a debt-to-equity ratio of 0.86, a quick ratio of 2.66 and a current ratio of 2.66. The company has a market capitalization of $33.27 billion, a price-to-earnings ratio of 39.30, a PEG ratio of 1.59 and a beta of 0.43.

Royalty Pharma (NASDAQ:RPRX) last announced its earnings results on Wednesday, May 6th. The biopharmaceutical company reported $1.30 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.22 by $0.08. Royalty Pharma had a return on equity of 29.25% and a net margin of 33.88%.The firm had revenue of $630.58 million during the quarter, compared to analysts’ expectations of $881.69 million. As a group, research analysts predict that Royalty Pharma PLC will post 5.05 EPS for the current year.

Royalty Pharma Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Wednesday, June 10th. Investors of record on Friday, May 15th were issued a dividend of $0.235 per share. This represents a $0.94 annualized dividend and a dividend yield of 1.6%. The ex-dividend date of this dividend was Friday, May 15th. Royalty Pharma’s dividend payout ratio is currently 63.95%.

Insider Activity

In other Royalty Pharma news, Director Gregory Norden sold 3,045 shares of the company’s stock in a transaction dated Thursday, May 14th. The shares were sold at an average price of $53.00, for a total transaction of $161,385.00. Following the completion of the sale, the director directly owned 191,803 shares in the company, valued at $10,165,559. This represents a 1.56% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Christopher Hite sold 150,000 shares of the firm’s stock in a transaction dated Tuesday, June 23rd. The shares were sold at an average price of $54.40, for a total value of $8,160,000.00. Following the completion of the sale, the executive vice president directly owned 559,399 shares in the company, valued at approximately $30,431,305.60. This represents a 21.14% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders have sold 427,800 shares of company stock valued at $23,333,723. 18.84% of the stock is owned by corporate insiders.

Royalty Pharma Company Profile

Royalty Pharma plc is a specialty finance company that acquires biopharmaceutical royalty interests and provides non-dilutive financing to drug developers and rights holders. The firm purchases future royalty streams, milestone-contingent payments and other revenue rights linked to approved and late-stage pharmaceutical and biotechnology products. By paying upfront consideration for these rights, Royalty Pharma seeks to generate long-term cash flows tied to the commercial performance of a diversified portfolio of medicines.

The company’s transaction structures include outright royalty purchases, structured financings and milestone arrangements tailored to the needs of innovator companies, academic institutions and investors.